Tai Chi may trim blood pressure and cholesterol for women over 45

Cardiometabolic risk climbs sharply in women during and after the menopausal transition, when blood pressure and cholesterol tend to worsen. Much exercise research is not designed around this group, and vigorous training is not always appealing or accessible for everyone. Tai Chi is a low-to-moderate intensity mind-body practice that could offer a gentler, non-pharmacological route to managing that risk. The open questions were whether benefits hold specifically in middle-aged and older women, and whether the dose and design of the programme change the outcome.

The reviewers searched five databases, PubMed, Web of Science, the Cochrane Library, Embase and CNKI, from inception to September 2025 for randomised controlled trials of structured Tai Chi programmes in women aged 45 or older. Eighteen trials met the criteria. Cardiometabolic outcomes were pooled using random-effects models, with moderator, sensitivity, publication bias and GRADE analyses conducted where appropriate. The team also examined whether baseline health status, the type of comparison group and the intervention dose helped explain differences between trials.

Tai Chi was associated with significant reductions in systolic and diastolic blood pressure, LDL cholesterol, triglycerides and total cholesterol. It made no clear difference to HDL cholesterol or fasting blood glucose. The catch is consistency: heterogeneity was substantial for most of the significant outcomes, and prediction intervals generally crossed the null, meaning the size of the benefit may vary considerably across comparable settings. Pulse wave velocity, a measure of arterial stiffness, could only be described narratively because just two studies reported it and they measured at different sites.

This is a women-specific look at a practice more often studied in mixed or clinical groups, so it extends rather than overturns what was known about Tai Chi and heart health. The pattern of results, with blood pressure and atherogenic lipids improving while HDL and glucose stayed put, gives a sharper picture of where any benefit concentrates. Exploratory subgroup analyses hinted that baseline health, the comparator and programme duration might partly explain why the trials disagreed. Larger trials with standardised Tai Chi prescriptions and consistent outcome measures are still needed.

For women in midlife and beyond who find running or lifting unappealing, this is evidence that a gentle, structured practice may still move meaningful numbers: blood pressure and cholesterol both shifted in the pooled results. It is not evidence that Tai Chi is the best tool available, nor a guarantee, since the benefit varied a great deal between trials. It is a reason to treat Tai Chi as a genuine option in the cardiometabolic toolkit rather than mere relaxation.